

PubMed

**Format:** Abstract**Full text links**

J Am Med Dir Assoc. 2018 Jan;19(1):59-64.e1. doi: 10.1016/j.jamda.2017.07.017. Epub 2017 Sep 9.

## Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions.

Stith SS<sup>1</sup>, Vigil JM<sup>2</sup>, Adams IM<sup>3</sup>, Reeve AP<sup>4</sup>.

### Author information

### Abstract

**BACKGROUND:** Co-prescribing of scheduled drugs is endemic in the United States, increasing health risks to patients and the burden on healthcare systems.

**PURPOSE:** We conducted a pragmatic historical cohort study to measure the effect of enrollment in a state-authorized United States' Medical Cannabis Program (MCP) on scheduled II-V drug prescription patterns.

**PROCEDURES:** Eighty-three chronic pain patients, who enrolled in the New Mexico MCP between April 1, 2010 and October 3, 2015, were compared with 42 nonenrolled patients over a 24-month period (starting 6 months before enrollment for the MCP patients) using the Prescription Monitoring Program. The outcome variables include baseline levels and pre- and postenrollment monthly trends in the number of drug prescriptions, distinct drug classes, dates prescription drugs were filled, and prescribing providers.

**FINDINGS:** Twenty-eight MCP patients (34%) and 1 comparison group patient (2%) ceased the use of all scheduled prescription medications by the last 6 months of the observation period. Age- and sex-adjusted regressions show that, although no statistically significant differences existed in pre-enrollment levels and trends, the postenrollment trend among MCP patients is statistically significantly negative for all 4 measures (decreases in counts of -0.02 to -0.04, P values between <.001 and .017), whereas the postenrollment trend is 0 among the comparison group. Controlling for time-invariant patient characteristics suggested that MCP patients showed statistically significantly lower levels across all 4 measures by 10 months postenrollment.

**CONCLUSIONS:** Legal access to cannabis may reduce the use of multiple classes of dangerous prescription medications in certain patient populations.

Copyright © 2017 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

**KEYWORDS:** Marijuana; Prescription Monitoring Program; cannabis; opioids; scheduled medications; substitution

PMID: 28899660 DOI: [10.1016/j.jamda.2017.07.017](https://doi.org/10.1016/j.jamda.2017.07.017)



---

**LinkOut - more resources**

